SYS6010 + SYH2051

SYS6010 + SYH2051 is an investigational combination therapy under clinical evaluation primarily for advanced and metastatic solid tumors, particularly EGFR-expressing breast cancer and gastrointestinal cancers. SYS6010 is a novel antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), while SYH2051 is a small molecule inhibitor of ataxia telangiectasia mutated (ATM) kinase, a key DNA damage response protein. The rationale for the combination is based on dual targeting of tumor cell proliferation (EGFR antagonism and cytotoxic payload) and impaired DNA repair (ATM inhibition), potentially enhancing antitumor efficacy in EGFR-expressing tumors as supported by preliminary clinical data demonstrating tolerability and antitumor activity in gastrointestinal tumors[1][3][4][5][7][9].